Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction

Journal of Cardiac Failure

Volumn 23, Issue 1, 2017, Pages 20-28

  Gandhi, Parul U ^a,b   Chow, Sheryl L ^c   Rector, Thomas S ^d,e   Krum, Henry ^f   Gaggin, Hanna K ^g   McMurray, John J ^h   Zile, Michael R ⁱ   Komajda, Michel ^j   McKelvie, Robert S ^k   Carson, Peter E ^l   Januzzi, James L ^g   Anand, Inder S ^d,e  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f MONASH UNIVERSITY   (Australia)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^j SORBONNE UNIVERSITÉ   (France)

^k MCMASTER UNIVERSITY   (Canada)

^l GEORGETOWN UNIVERSITY   (United States)

more..

Author keywords

biomarkers; Heart failure; insulin like growth factor binding protein 7; preserved left ventricular function; prognosis

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; IRBESARTAN; SOMATOMEDIN BINDING PROTEIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; TETRAZOLE DERIVATIVE;

AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL ARTICLE; CONTROLLED STUDY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; EPIDEMIOLOGY; HEART FAILURE; HEART STROKE VOLUME; HOSPITALIZATION; MORTALITY; MULTICENTER STUDY; PHYSIOLOGY; PROGNOSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; TIME FACTOR; TRENDS; UNITED STATES;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CAUSE OF DEATH; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HOSPITALIZATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; PROGNOSIS; RISK FACTORS; STROKE VOLUME; SURVIVAL RATE; TETRAZOLES; TIME FACTORS; UNITED STATES;

EID: 84979713222     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2016.06.006     Document Type: Article

References (27)

1. 1 Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M., et al. Heart disease and stroke statistics–2015 update: a report from the American Heart Association. Circulation 131 (2015), e29–322.
2. 2 Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
3. 3 Steinberg, B.A., Zhao, X., Heidenreich, P.A., Peterson, E.D., Bhatt, D.L., Cannon, C.P., et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 126 (2012), 65–75.
4. 4 Bhatia, R.S., Tu, J.V., Lee, D.S., Austin, P.C., Fang, J., Haouzi, A., et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 355 (2006), 260–269.
5. 5 Fonarow, G.C., Stough, W.G., Abraham, W.T., Albert, N.M., Gheorghiade, M., Greenberg, B.H., et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 50 (2007), 768–777.
6. 6 Meta-analysis Global Group in Chronic Heart Failure (MAGGIC). The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. Eur Heart J 33 (2012), 1750–1757.
7. 7 Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., Casey, D.E. Jr, Drazner, M.H., et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 (2013), e240–327.
8. 8 Massie, B.M., Carson, P.E., McMurray, J.J., Komajda, M., McKelvie, R., Zile, M.R., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 359 (2008), 2456–2467.
9. 9 Pitt, B., Pfeffer, M.A., Assmann, S.F., Boineau, R., Anand, I.S., Claggett, B., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
10. 10 Redfield, M.M., Chen, H.H., Borlaug, B.A., Semigran, M.J., Lee, K.L., Lewis, G., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309 (2013), 1268–1277.
11. 11 Komajda, M., Lam, C.S., Heart failure with preserved ejection fraction: a clinical dilemma. Eur Heart J 35 (2014), 1022–1032.
12. 12 van Veldhuisen, D.J., Linssen, G.C., Jaarsma, T., van Gilst, W.H., Hoes, A.W., Tijssen, J.G., et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 61 (2013), 1498–1506.
13. 13 Tschope, C., Kasner, M., Westermann, D., Gaub, R., Poller, W.C., Schultheiss, H.P., The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 26 (2005), 2277–2284.
14. 14 Yu, C.M., Sanderson, J.E., Shum, I.O., Chan, S., Yeung, L.Y., Hung, Y.T., et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 17 (1996), 1694–1702.
15. 15 Chugh, S., Ouzounian, M., Lu, Z., Mohamed, S., Li, W., Bousette, N., et al. Pilot study identifying myosin heavy chain 7, desmin, insulin-like growth factor 7, and annexin A2 as circulating biomarkers of human heart failure. Proteomics 13 (2013), 2324–2334.
16. 16 Motiwala, S.R., Szymonifka, J., Belcher, A., Weiner, R.B., Baggish, A.L., Gaggin, H.K., et al. Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. J Cardiovasc Transl Res 7 (2014), 250–261.
17. 17 Gandhi, P.U., Gaggin, H.K., Sheftel, A.D., Belcher, A.M., Weiner, R.B., Baggish, A.L., et al. Prognostic usefulness of insulin-like growth factor-binding protein 7 in heart failure with reduced ejection fraction: a novel biomarker of myocardial diastolic function?. Am J Cardiol 114 (2014), 1543–1549.
18. 18 Krum, H., Elsik, M., Schneider, H.G., Ptaszynska, A., Black, M., Carson, P.E., et al. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy. Circ Heart Fail 4 (2011), 561–568.
19. 19 Komajda, M., Carson, P.E., Hetzel, S., McKelvie, R., McMurray, J., Ptaszynska, A., et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 4 (2011), 27–35.
20. 20 Kashani, K., Al-Khafaji, A., Ardiles, T., Artigas, A., Bagshaw, S.M., Bell, M., et al. Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care, 17, 2013, R25.
21. 21 Degeorges, A., Wang, F., Frierson, H.F. Jr, Seth, A., Sikes, R.A., Distribution of IGFBP-rP1 in normal human tissues. J Histochem Cytochem 48 (2000), 747–754.
22. 22 Zhu, S., Xu, F., Zhang, J., Ruan, W., Lai, M., Insulin-like growth factor binding protein-related protein 1 and cancer. Clin Chim Acta 431 (2014), 23–32.
23. 23 Guo, X.H., Liu, L.X., Zhang, H.Y., Zhang, Q.Q., Li, Y., Tian, X.X., et al. Insulin-like growth factor binding protein-related protein 1 contributes to hepatic fibrogenesis. J Dig Dis 15 (2014), 202–210.
24. 24 Komiya, E., Furuya, M., Watanabe, N., Miyagi, Y., Higashi, S., Miyazaki, K., Elevated expression of angiomodulin (AGM/IGFBP-rP1) in tumor stroma and its roles in fibroblast activation. Cancer Sci 103 (2012), 691–699.
25. 25 Paulus, W.J., Tschope, C., A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 62 (2013), 263–271.
26. 26 Damman, K., Perez, A.C., Anand, I.S., Komajda, M., McKelvie, R.S., Zile, M.R., et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol 64 (2014), 1106–1113.
27. 27 Gandhi, P.U., Redfield, M.M., Chen, H.H., Stevens, S.R., Anstrom, K.J., Gaggin, H.K., et al. Insulin-like growth factor-binding protein 7 as a biomarker of diastolic dysfunction and functional capacity: results from the phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in heart failure with preserved ejection fraction (RELAX) trial. Circulation, 132, 2015, A14023.